1.62
Zentalis Pharmaceuticals Inc stock is traded at $1.62, with a volume of 425.47K.
It is down -3.57% in the last 24 hours and up +8.72% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.68
Open:
$1.7
24h Volume:
425.47K
Relative Volume:
0.62
Market Cap:
$116.86M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3568
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+1.89%
1M Performance:
+8.72%
6M Performance:
+31.71%
1Y Performance:
-45.82%
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZNTL
Zentalis Pharmaceuticals Inc
|
1.62 | 121.19M | 0 | -292.19M | -208.41M | -4.54 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
Jun-20-24 | Downgrade | UBS | Buy → Neutral |
Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Jul-12-22 | Initiated | Cowen | Outperform |
Apr-06-22 | Initiated | Wells Fargo | Overweight |
Oct-07-21 | Resumed | Jefferies | Buy |
Sep-30-21 | Initiated | Stifel | Buy |
Sep-29-21 | Initiated | Oppenheimer | Outperform |
May-21-21 | Initiated | UBS | Buy |
Jan-20-21 | Initiated | Wedbush | Outperform |
Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-27-20 | Initiated | H.C. Wainwright | Buy |
Apr-28-20 | Initiated | Guggenheim | Buy |
Apr-28-20 | Initiated | Jefferies | Buy |
Apr-28-20 | Initiated | Morgan Stanley | Overweight |
Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis to present azenosertib data at cancer therapeutics conference - Investing.com India
Zentalis Pharmaceuticals Announces Acceptance of Azenosertib Abstracts for Presentation at AACR-NCI-EORTC Conference - Quiver Quantitative
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarGap Up & Stepwise Entry and Exit Trade Signals - newser.com
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockWall Street Watch & Risk Managed Investment Signals - newser.com
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - ADVFN Ltd
Can Zentalis Pharmaceuticals Inc. hit a new high this monthTrade Risk Summary & Weekly High Potential Stock Alerts - newser.com
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Wealth Enhancement Advisory Services LLC - Defense World
What institutional flow reveals about Zentalis Pharmaceuticals Inc.Market Sentiment Review & Community Trade Idea Sharing - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
What earnings revisions data tells us about Zentalis Pharmaceuticals Inc.Weekly Trade Report & Entry Point Confirmation Alerts - newser.com
Full technical analysis of Zentalis Pharmaceuticals Inc. stockJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Using data filters to optimize entry into Zentalis Pharmaceuticals Inc.Watch List & Verified Technical Trade Signals - newser.com
Zentalis Pharmaceuticals' (ZNTL) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Key metrics from Zentalis Pharmaceuticals Inc.’s quarterly dataQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Short interest data insights for Zentalis Pharmaceuticals Inc.2025 Fundamental Recap & Verified Short-Term Plans - newser.com
Pattern recognition hints at Zentalis Pharmaceuticals Inc. upsideJuly 2025 Review & Target Return Focused Picks - newser.com
How to build a dashboard for Zentalis Pharmaceuticals Inc. stockMarket Activity Report & Smart Swing Trading Techniques - newser.com
Positive week for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional investors who lost 48% over the past year - simplywall.st
What analysts say about Zentalis Pharmaceuticals Inc stockDebt-to-Equity Ratio Analysis & Ride the Trends That Billionaires Follow - earlytimes.in
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
400,000 Stock Options at $1.54: Zentalis Pharmaceuticals Welcomes New Chief Legal Officer with Major Grant - Stock Titan
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc. - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):